Molecular Cancer Research

Molecular Cancer Research is a peer-reviewed journal published by the American Association for Cancer Research, issued monthly. Founded in 2002 on the predecessor Cell Growth & Differentiation, established in 1990, it publishes original research at the molecular level of cancer.《分子癌症研究》（Molecular Cancer Research）是一份由美国癌症研究协会（American Association for Cancer Research，简称 AACR）出版的同行评审学术期刊，月刊。该刊创刊于 2002 年，前身为 1990 年创办的《细胞生长与分化》，刊载肿瘤分子层面的原创性研究。

Scope

The journal's editorial stance sets molecular mechanistic evidence as the threshold, requiring that a paper include mechanistic analysis at the molecular level together with functional validation in vivo or in vitro, rather than merely describing correlations with tumour phenotype. The journal also emphasises translational orientation, holding that molecular findings should point toward possible therapeutic intervention. Its principal subject areas include:本刊的取稿立场是「以分子层面的机制证据为门槛」，即要求论文须包含分子机制解析，并配以体内或体外的功能验证，而非仅作肿瘤表型的相关性描述。刊物同时强调转化导向，认为分子层面的发现须指向治疗干预的可能。收文覆盖的主要方向包括：

• Tumour molecular mechanisms: the function of oncogenes and tumour suppressors, signalling networks, and epigenetic regulation.肿瘤分子机制： 癌基因与抑癌基因的功能、信号转导网络与表观遗传调控。
• Targeted therapy and resistance: identification of molecular targets, the mechanism of targeted agents, resistance mechanisms, and combination strategies.靶向治疗与耐药： 分子靶点鉴定、靶向药物机制、耐药机制与联合用药策略。
• The tumour microenvironment: the molecular roles of tumour-associated stroma, immune cells and vasculature in tumour progression.肿瘤微环境： 肿瘤相关基质、免疫细胞与血管在肿瘤进展中的分子作用。
• Molecular diagnosis and stratification: molecular classification, prognostic markers and markers predictive of treatment response.分子诊断与分层： 分子分型、预后标志物与治疗反应预测标志物。
• Experimental models and methodology: genetically engineered animal models, organoids, and molecular pharmacological methodology.实验模型与方法学： 基因工程动物模型、类器官与分子药理学方法学。

The journal is a hybrid title. The subscription route charges authors nothing, while open access carries an article processing charge. The publisher publishes neither an acceptance rate nor a review duration for this title, and the library's previous notes of relatively easy acceptance and a relatively slow four to eight weeks had no official basis and have been deleted. The journal is indexed in the Science Citation Index Expanded.该刊属混合出版模式：订阅路线不向作者收费，选择开放获取需支付文章处理费。出版方不公布该刊录用比例与审稿时长，库内原记录用率「相对容易」与审稿「相对较慢，4 至 8 周」均无官方依据，已删除。该刊被科学引文索引扩展版收录。

History

• Founding and predecessor (1990–2002): the predecessor Cell Growth & Differentiation was founded in 1990, and the present title was adopted in 2002 with the volume numbering continuing. The library's history start of 2002 and its record of the former title coexist, the two corresponding to the year the present name was adopted and to the start of the lineage respectively.创刊与前身（1990–2002）： 本刊的前身《细胞生长与分化》创刊于 1990 年，2002 年起改用现名并承接卷号；库内沿革起点 2002 年与前身刊名记录并存，两说分别对应现名启用年与谱系起点。^[1]
• Society affiliation: the journal has been an official title of the American Association for Cancer Research since its founding. That association, established in 1907, is the principal academic organisation of American cancer research and publishes ten journals, of which this is one.学会归属： 本刊自创刊起即为美国癌症研究协会的官方刊物；该协会成立于 1907 年，是美国癌症研究领域的主要学术组织，旗下共十种期刊，本刊为其一。^[1]
• Current editor: Massimo Loda serves as editor-in-chief at the Sandra and Edward Meyer Cancer Center of Weill Cornell Medical College, his editorship recorded in the American Association for Cancer Research's 2025 annual report listing of editors.现任主编： 马西莫·洛达（Massimo Loda）任主编，供职于威尔康奈尔医学院桑德拉与爱德华·迈耶癌症中心；其主编身份见于美国癌症研究协会 2025 年度报告编辑名录。^[2]
• Board structure: the editorial board comprises deputy editors, senior editors and an assistant editor, the deputy editors including Andrew H. Beck, Christina Curtis and James J. Manfredi, with more than twenty senior editors forming the journal's molecular review capacity.编委会架构： 编委会由副主编、资深编辑与助理编辑构成，副主编含安德鲁·贝克、克里斯蒂娜·柯蒂斯、詹姆斯·曼弗雷迪等，资深编辑逾二十人，构成该刊的分子机制评审力量。^[2]
• Metric trend: the 2025 impact factor of 5.2, together with the CiteScore, places the journal in the medical class 2 zone of the Chinese Academy of Sciences ranking, with oncology and biochemistry and molecular biology both at zone 2.指标走势： 影响因子自 2025 年的 5.2 与引用分数共同刻画该刊位置；中科院分区中列于医学大类二区、肿瘤学与生化分子生物学小类二区。^[1]
• Selection threshold and screening: according to the association's 2025 submission report, the principal reasons for desk rejection are a lack of functional validation data or a mismatch with the journal's submission preferences, which corroborates the editorial stance of setting molecular mechanistic evidence as the threshold.取稿门槛与初筛： 据该协会 2025 年投稿年度报告，初筛退稿的最主要原因是研究缺乏功能验证数据或与刊物收稿偏好不匹配；这与该刊以分子机制证据为门槛的取稿立场相互印证。^[1]

Editors

The journal operates under a single editor-in-chief appointed by the American Association for Cancer Research, with a board comprising deputy editors, senior editors and an assistant editor, and manuscripts submitted through the society's unified submission system. The society publishes no editorial process detail beyond the journal's volume.本刊实行主编负责制，主编由美国癌症研究协会任命并主持编辑部，编委会由副主编、资深编辑与助理编辑构成，稿件经学会统一的投稿系统投递。官方不公布除刊物体量之外的编辑流程细节。

• Massimo Loda (current editor-in-chief): professor of pathology and laboratory medicine at Weill Cornell Medical College, working on metabolic reprogramming and molecular pathology in prostate cancer, whose editorship is recorded in the association's 2025 annual report.马西莫·洛达（现任主编）： 威尔康奈尔医学院病理学与实验医学教授，研究方向为前列腺癌代谢重编程与分子病理学；其主编身份见于协会 2025 年度报告。^[2]
• Deputy editors: the deputy editors include Andrew H. Beck on artificial intelligence in pathology, Christina Curtis on computational oncology, James J. Manfredi on cell signalling and Kathryn E. Wellen on lipid metabolism, covering the journal's principal molecular directions.副主编构成： 副主编含安德鲁·贝克（病理人工智能）、克里斯蒂娜·柯蒂斯（计算肿瘤学）、詹姆斯·曼弗雷迪（细胞信号）与凯瑟琳·韦伦（脂类代谢）等，覆盖该刊的主要分子方向。^[2]
• The earlier title: from 1990 to 2002 the journal appeared under the name Cell Growth & Differentiation, a period that formed its early volumes and editorial structure, for which the publisher has not published a list of first and successive editors.前身刊时期： 1990 至 2002 年本刊以《细胞生长与分化》为名出版，该时期为其早期卷期与编辑架构的形成阶段，具体首任与历任主编名单出版方未公布。^[1]
• Acceptance and speed: the publisher publishes neither an acceptance rate nor a review duration for this title. The library's previous notes of relatively easy acceptance and a relatively slow four to eight weeks had no official basis and have been deleted.录用与时效： 出版方不公布该刊录用率与审稿时长；库内原记录用率「相对容易」与审稿「相对较慢，4 至 8 周」均无官方依据，已删除。^[1]
• Standing in the field: the journal is one of the principal titles in tumour molecular mechanism and targeted therapy, its mechanistic papers routinely serving as base citations for later target validation and drug development.学科地位： 该刊是肿瘤分子机制与靶向治疗方向的主要刊物之一，其分子机制论文常成为后续靶点验证与药物开发的基础引用来源。^[1]